Consequences of Long‐Term Proton Pump Blockade: Insights from Studies of Patients with Gastrinomas
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Proton pump inhibitors are being increasingly used and for longer periods of time, especially in patients with gastroesophageal reflux disease. Each of these trends has led to numerous studies and reviews of the potential risk‐benefit ratio of the long‐term use of proton pump inhibitors. Both long‐term effects of hypergastrinaemia due to the profound acid suppression caused by proton pump inhibitors as well as the effects of hypo‐/achlorhydria per se have been raised and studied. Potential areas of concern that have been raised in the long‐term use of proton pump inhibitors, which could alter this risk‐benefit ratio include: gastric carcinoid formation; the development of rebound acid hypersecretion when proton pump inhibitor treatment is stopped; the development of tolerance; increased oxyntic gastritis in H. pylori patients and the possibility of increasing the risk of gastric cancer; the possible stimulation of growth of non‐gastric tumours due to hypergastrinaemia; and the possible effect of the hypo/achlorhydria on nutrient absorption, particularly iron and vitamin B12. Because few patients with idiopathic gastro‐oesophageal reflux disease/peptic ulcer disease have been treated long‐term (i.e., >10 years), there is little known to address the above areas of potential concern. Most patients with gastrinomas with Zollinger‐Ellison syndrome have life‐long hypergastrinaemia, require continuous proton pump inhibitors treatment and a number of studies report results of >5–10 years of tratment and follow‐up. Therefore, an analysis of Zollinger‐Ellison syndrome patients can provide important insights into some of the safety concerns raised above. In this paper, results from studies of Zollinger‐Ellison syndrome patients and other recent studies dealing with the safety concerns above, are briefly reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum, H. L., Arnestad, J. S., Brenna, E., Eide, I., Syversen, U., & Sandvik, A. K. (1996) · Gut · doi:10.1136/gut.39.5.649 · Cited by 243
Rebound acid hypersecretion after long-term inhibition of gastric acid secretion.
Fossmark, R., Johnsen, G., Johanessen, E., & Waldum, H. L. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02271.x · Cited by 119
Cited by
Jensen, R. T., Cadiot, G., Brandi, M. L., de Herder, W. W., Kaltsas, G., Komminoth, P., Scoazec, J.-Y., Salazar, R., Sauvanet, A., & Kianmanesh, R. (2012) · Neuroendocrinology · doi:10.1159/000335591 · Cited by 622
Self-citationNANETS Treatment Guidelines: Well-Differentiated Neuroendocrine Tumors of the Stomach and Pancreas
Kulke, M. H., Anthony, L. B., Bushnell, D. L., de Herder, W. W., Goldsmith, S. J., Klimstra, D. S., Marx, S. J., Pasieka, J. L., Pommier, R. F., Yao, J. C., et al. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb168 · Cited by 574
Self-citationfor the SIF-AIGO-FIMMG Group, Scarpignato, C., on behalf of the Italian Society of Pharmacology, T. I. A. O. H. G., Gatta, L., Zullo, A., & Blandizzi, C. (2016) · BMC Medicine · doi:10.1186/s12916-016-0718-z · Cited by 469
“portant insights into some of the safety issues, concerning long-term acid suppression [183].”
BackgroundSafety of the long-term use of proton pump inhibitors
Thomson, A. B. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i19.2323 · Cited by 315
Proton pump inhibitors: an update of their clinical use and pharmacokinetics
Shi, S., & Klotz, U. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0538-y · Cited by 314
Metadata
- Authors
- Jensen, R. T.
- Venue
- Basic & Clinical Pharmacology & Toxicology
- Publisher
- Wiley
- Published
- 2006-01
- Volume
- 98
- Issue
- 1
- Pages
- 4-19
- ISSN
- 1742-7835 (ISSN-L)
- 1742-7843
- OpenAlex
- W2156027010
- Cited by
- 131
- References
- 2
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Consequences of Long‐Term Proton Pump Blockade: Insights from Studies of Patients with Gastrinomas. https://app.cochat.ai/papers/10.1111/j.1742-7843.2006.pto_378.x
- The paper
- Jensen, R. T. (2006). Consequences of Long‐Term Proton Pump Blockade: Insights from Studies of Patients with Gastrinomas. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/j.1742-7843.2006.pto_378.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.